SPTAN1, APC, and FGFR3 Mutation Status and APOBEC Mutation Signatures are Predictive of Mitomycin C Response in Non-muscle-invasive Bladder Cancer

Sylvester, 2006, Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials, Eur Urol, 49, 466, 10.1016/j.eururo.2005.12.031 Sylvester, 2021, European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel, Eur Urol, 79, 480, 10.1016/j.eururo.2020.12.033 Lindskrog, 2021, An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer, Nat Commun, 12, 2301, 10.1038/s41467-021-22465-w Lindgren, 2020, The DaBlaCa-13 study: short-term, intensive chemoresection versus standard adjuvant intravesical instillations in non-muscle-invasive bladder cancer—a randomised controlled trial, Eur Urol, 78, 856, 10.1016/j.eururo.2020.07.009 Wang, 2018, CXCL5 promotes mitomycin C resistance in non-muscle invasive bladder cancer by activating EMT and NF-κB pathway, Biochem Biophys Res Commun, 498, 862, 10.1016/j.bbrc.2018.03.071 McShane, 2005, REporting recommendations for tumour MARKer prognostic studies (REMARK), Br J Cancer, 93, 387, 10.1038/sj.bjc.6602678 Taber, 2020, Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis, Nat Commun, 11, 4858, 10.1038/s41467-020-18640-0 Lamy, 2016, Paired exome analysis reveals clonal evolution and potential therapeutic targets in urothelial carcinoma, Cancer Res, 76, 5894, 10.1158/0008-5472.CAN-16-0436 Alexandrov, 2013, Signatures of mutational processes in human cancer, Nature, 500, 415, 10.1038/nature12477 Roberts, 2013, An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers, Nat Genet, 45, 970, 10.1038/ng.2702 Kim, 2016, Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors, Nat Genet, 48, 600, 10.1038/ng.3557 Rosenthal, 2019, Neoantigen-directed immune escape in lung cancer evolution, Nature, 567, 479, 10.1038/s41586-019-1032-7 Bracci, 2014, Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer, Cell Death Differ, 21, 15, 10.1038/cdd.2013.67 Meeks, 2020, Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes, Nat Rev Urol, 17, 259, 10.1038/s41585-020-0304-1 Zhang, 2016, MicroRNA-128-3p regulates mitomycin C-induced DNA damage response in lung cancer cells through repressing SPTAN1, Oncotarget, 8, 58098, 10.18632/oncotarget.12300 Prawira, 2019, Assessment of PARP4 as a candidate breast cancer susceptibility gene, Breast Cancer Res Treat, 177, 145, 10.1007/s10549-019-05286-w Stefanski, 2020, Wnt-independent and Wnt-dependent effects of APC loss on the chemotherapeutic response, Int J Mol Sci, 21, 7844, 10.3390/ijms21217844 Tomasz, 1995, Mitomycin C: small, fast and deadly (but very selective), Chem Biol, 2, 575, 10.1016/1074-5521(95)90120-5 Wang, 2019, Fibroblast growth factor receptor 3 alterations and response to PD-1/PD-L1 blockade in patients with metastatic urothelial cancer, Eur Urol, 76, 599, 10.1016/j.eururo.2019.06.025 Sweis, 2016, Molecular drivers of the non–T-cell-inflamed tumor microenvironment in urothelial bladder cancer, Cancer Immunol Res, 4, 563, 10.1158/2326-6066.CIR-15-0274 Fridman, 2017, The immune contexture in cancer prognosis and treatment, Nat Rev Clin Oncol, 14, 717, 10.1038/nrclinonc.2017.101 Granadillo Rodríguez, 2020, The interesting relationship between APOBEC3 deoxycytidine deaminases and cancer: a long road ahead, Open Biol, 10, 10.1098/rsob.200188 Razzak, 2013, APOBEC—a double-edged sword, Nat Rev Clin Oncol, 10, 488, 10.1038/nrclinonc.2013.138 Györffy, 2006, Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations, Int J Cancer, 118, 1699, 10.1002/ijc.21570 Bellmunt, 2020, Genomic predictors of good outcome, recurrence, or progression in high-grade T1 non-muscle-invasive bladder cancer, Cancer Res, 80, 4476, 10.1158/0008-5472.CAN-20-0977 Hurst, 2017, Genomic subtypes of non-invasive bladder cancer with distinct metabolic profile and female gender bias in KDM6A mutation frequency, Cancer Cell, 32, 10.1016/j.ccell.2017.08.005 Laukhtina, 2021, Catalog of prognostic tissue-based biomarkers in patients treated with neoadjuvant systemic therapy for urothelial carcinoma of the bladder: a systematic review, Urol Oncol, 39, 180, 10.1016/j.urolonc.2020.12.019